Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Saved in:
| Title: | Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. |
|---|---|
| Authors: | Shivapurkar, Narayan1 (AUTHOR), Gay, Martha D.1 (AUTHOR), He, Aiwu2 (AUTHOR), Chen, Wenqiang1 (AUTHOR), Golnazar, Shermineh3 (AUTHOR), Cao, Hong1 (AUTHOR), Duka, Tetyana1 (AUTHOR), Kallakury, Bhaskar4 (AUTHOR), Vasudevan, Sona3 (AUTHOR), Smith, Jill P.1,2 (AUTHOR) jps261@georgetown.edu |
| Source: | International Journal of Molecular Sciences. Feb2023, Vol. 24 Issue 4, p3625. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
